Co-Diagnostics (CODX) Stock Forecast: StockMap's 2-Week Call

CODX stock forecast: StockMap's model calls Co-Diagnostics Strong Underperform for the two weeks after the Nov 19 close: it expects CODX to trail the growth index. It is a call on the gap, not a price target. Right in 5 of 6 two-week windows on CODX since Aug 21; by chance, a call on the same dates was right 59% of the time.

Co-Diagnostics last closed at $0.16, -20.00% on the session.

Against the IVW growth benchmark the position is -17.67% over the forecast window.

Co-Diagnostics' market cap is $1.66M as of November 19, 2026.

Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -69 (behind).

Where CODX sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

49 daily calls for CODX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Co-Diagnostics in the 3rd percentile on return on equity, where 100 is best.

Co-Diagnostics is classified under Health Care / Health Care Equipment & Supplies.

StockMap tracks Co-Diagnostics as the 140th largest of the 141 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.

Across that group the current two-week reads are 69 Neutral, 55 Moderate Underperform, 14 Strong Underperform and 3 Moderate Outperform.

On that composite Co-Diagnostics ranks 138th of 141 in the group, against a group median of -0.18.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Co-Diagnostics (CODX) — StockMap 2-week forecast & tracked accuracy